Trial · NCT07228221
Standalone iStent Infinite and iDose TR for Management of Moderate to Severe Open Angle Glaucoma
NCT07228221, Phase 4, Recruiting, Jonathon Myers
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Standalone iStent Infinite and iDose TR for Management of Moderate to Severe Open Angle Glaucoma. Trials, record NCT07228221. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07228221
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Standalone iStent Infinite and iDose TR for Management of Moderate to Severe Open Angle Glaucoma
- NCT number
- NCT07228221
- Status
- Recruiting
- Phases
- Phase 4
- Enrollment
- 20 participants, estimated
- Lead sponsor
- Jonathon Myers
- Conditions
- Open Angle Glaucoma, Pigmentary Glaucoma, Pseudoexfoliation Glaucoma
- Interventions
- iStent infinite trabecular micro-bypass system model iS3, iDose TR (Travoprost intracameral Implant) 75mcg
- First posted
- 2025-11-14
- Last updated
- 2025-11-14
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | IOP reduction from baseline | Diurnal IOP reduction from baseline at 12 months | a logistic regression model will be used for the imputation of missing values, using the 12-month performance outcome as dependent variable, and sex, race, age, baseline IOP, number of IOP-lowering medications used at baseline, last IOP and number of medications at the 6-month visit or later as explanatory variables. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07228221
GET https://conductscience.org/api/trials/v1/NCT07228221/registered